Event Fulfillment Coordinator

Tiny Health, a microbiome intelligence platform, has been ranked No. 208 on the 2026 Inc. 5000 list of America's fastest-growing private companies. The Austin-based company reported 1,624% revenue growth between 2022 and 2025, placing fourth among biotech companies on the list. Founded in 2020 by CEO Cheryl Sew Hoy, Tiny Health provides gut and vaginal microbiome testing across different life stages. The company recently published three studies, including a randomised controlled trial showing personalised microbiome interventions reduced infants' odds of allergic conditions by 83%. Tiny Health's B2B platform now serves over 5,000 healthcare practitioners and partners with organisations including Mayo Clinic, Superpower, and Fullscript. The company is on track to triple revenue by year's end.

Tiny Health named No. 208 on the 2026 Inc. 5000 List of America's fastest-growing private companies. Microbiome innovator recognized for 1,624% three-year revenue growth, earning a place among the nation's most successful independent businesses. AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) - Tiny Health, the microbiome intelligence platform for precision health at every stage of life, today announced it has been ranked No. 208 on the 2026 Inc. 5000, the annual list of the fastest-growing private companies in America. Among Biotech companies on this year's list, Tiny Health ranked fourth, with 1,624% growth between 2022 and 2025, and on pace to triple revenue by year's end. "I founded Tiny Health in 2020, when my son was one week old. Potential investors kept telling me the market was too small and that pediatrics was too niche. Today, our fastest-growing segment is adults, and we're the market leader in gut and vaginal microbiome testing from the first 1,000 days to healthy aging," said Cheryl Sew Hoy, founder and CEO of Tiny Health. Over the past year, Tiny Health has published three studies in rapid succession. Its first randomized controlled trial published in Pediatric Allergy and Immunology, Infant Restore, showed that personalized microbiome interventions reduced infants' odds of allergic conditions by 83% [1]. The company also published research linking early-life gut microbiome profiles to eczema and food allergies in Frontiers in Microbiomes [2], and a preprint demonstrating that its proprietary technology outperforms industry benchmarks in detecting clinically-relevant microbes across all life stages [3]. The science is matched by commercial momentum, as the company continues to scale its Powered by Tiny B2B platform, now embedded in the workflows of more than 5,000 healthcare practitioners and integrated with partners including Superpower, Joi + Blokes, Resbiotic, Fullscript, Mayo Clinic, Pritikin, and leading digital health platforms. "We're honored to be named to this year's Inc. 5000 list, and our growth trajectory reflects the urgent demand in the market, from families trying to understand what's happening beneath the surface of their health and take action, to health practitioners and digital health companies integrating our microbiome insights into their patient experiences," Sew Hoy said. "We're proof that you can build a rigorous science company and a fast-growing one at the same time. We're redefining the microbiome as a standard layer of personalized health. This is the next frontier of medicine." Sew Hoy's story is featured among this year's honoree profiles, along with the full Inc. 5000 list available at www.inc.com/inc5000. This year's Inc. 5000 recognizes a new class of companies redefining what growth looks like. From AI and advanced manufacturing to healthcare, consumer products, and professional services, these businesses are expanding their impact, creating jobs and proving that entrepreneurial ambition continues to fuel the U.S. economy. Among the 5,000 companies on the list, the median three-year revenue growth rate was 130%, and those companies have collectively added more than 627,208 jobs to the U.S. economy over the past three years. "Every company on the Inc. 5000 has a story of perseverance, smart decision making, and a refusal to sit still," says Mike Hofman, editor-in-chief of Inc. "Their growth reflects more than strong financial performance-it reflects creativity, resilience, and the customer focus required to build companies that make a lasting impact. We congratulate all honorees on this significant achievement." About Tiny Health Tiny Health is advancing lifelong health, from the first 1,000 days to the last, and addressing chronic disease through precision microbiome science. Founded in 2020 and built by microbiome scientists and physicians, its testing platform reveals whether your microbiome is trending toward resilience or imbalance using shotgun metagenomics, proprietary AI, and one of the world's largest longitudinal datasets. Trusted by families and health practitioners alike, its research-backed gut and vaginal tests are redefining the microbiome as a cornerstone of personalized health through every life stage. Learn more at tinyhealth.com and poweredbytiny.com. Inc. 5000 List Methodology Companies on the 2026 Inc. 5000 are ranked according to percentage revenue growth from 2022 to 2025. To qualify, companies must have been founded and generating revenue by March 31, 2022. They must be U.S.-based, privately held, for-profit, and independent - not subsidiaries or divisions of other companies - as of December 31, 2025. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2022 is $100,000; the minimum for 2025 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping its future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit www.inc.com. Media Contact Hannah Goering Tiny Health [email protected] Tiny Health ranks No. 208 on the 2026 Inc. 5000 List. Tiny Health, the microbiome intelligence platform for precision health at every stage of life, today announced it has been ranked No. 208 on the 2026 Inc. 5000, the annual list of the fastest-growing private companies in America. Among Biotech companies on this year's list, Tiny Health ranked fourth, with 1,624% growth between 2022 and 2025. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Alabama Cultural Times do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Leche and Tiny Health launch first clinical study of donor breast milk's effect on formula-fed infants' Gut Health. Provided by Business Wire Jul 20, 2026, 2:00:00 PM The 100-family trial will measure whether a small daily amount of donor breast milk shifts a formula-fed infant's gut toward a healthier, more breastfed-like pattern Leche, the first shelf-stable, consumer-driven donor breast milk, and Tiny Health, the at-home microbiome testing company for every stage of life, today announced a joint clinical study examining how donor breast milk affects gut health in formula-fed infants. It is among the first studies to apply modern microbiome science to donor milk specifically, and the first to measure what happens when a small daily amount is added on top of formula. Leche's donor breast milk sachets alongside Tiny Health's Gut Health Test, the tools families will use as part of the new joint study. Leche is 100% human donor breast milk powder from medically screened donors, triple-tested at every stage for safety and quality, processed in an FDA-registered facility following GMP guidelines. Each convenient 8g sachet reconstitutes into 2oz of breast milk, making it easier and safer to access donor milk. "For years the conversation has been breast versus formula, as if those are the only two options a family gets," said Trish Clifford, co-founder of Leche. "Most parents end up somewhere in between, and until now nobody has actually studied what that middle ground does for a baby's health. We built Leche because donor milk deserved to be a safe and accessible option instead of a workaround. This study is about giving that option the science to back it up." The science on breast milk's role in infant gut development is well established. A baby's gut is home to trillions of bacteria, and establishing the right ones early is linked to better digestion, immunity and long-term health. Research consistently shows that even a little breast milk helps grow those protective bacteria, largely because of human milk oligosaccharides, a family of roughly 150 to 200 sugars unique to breast milk that feed the gut's good bacteria directly. Formula can now replicate one or two of them, but real breast milk, including powdered donor milk, delivers the full range, since the sugars survive pasteurization intact. What has not been established, and what this study hopes to prove, is whether a modest daily amount of donor milk, layered into a formula-fed baby's routine, moves the needle for the roughly two-thirds of American babies who receive and rely on formula at some point in their first year. "This is one of the first studies to examine whether adding a small, consistent amount of donor breast milk to an otherwise formula-fed infant's diet can produce measurable shifts in microbiome composition and function," said Cheryl Sew Hoy, Founder and CEO of Tiny Health. "Using shotgun metagenomics, we are eager to see whether babies' gut microbiomes become better equipped to use the unique sugars found in human milk - and whether even a small daily amount can help beneficial bacteria take hold during this important window of development." The study follows a straightforward before-and-after design. Tiny Health will test 100 healthy, full-term, formula-fed babies' guts at enrollment, families will add Leche powdered donor breast milk to daily feeds for a month, and Tiny Health will retest independently at the end. Researchers will look at whether levels of Bifidobacterium, the beneficial bacteria that dominate a healthy breastfed baby's gut, increase, whether the gut becomes better equipped to use breast milk sugars, and whether the overall microbiome shifts toward a more breastfed-like pattern. Sign-ups open officially August 1 and will close at 100 participants or August 15, whichever comes first. Enrolled families will begin the study in September, with results expected later this year. About Leche Leche pioneered shelf-stable, consumer driven donor breast milk, and remains the category leader in making real donor breast milk accessible to everyday families. Founded by mothers and breast milk donors Jenney Korasick and Trish Clifford, Leche is modernizing breast milk through an innovative freeze-drying process that preserves its nutrients while giving parents the ultimate flexibility in feeding. Leche is available direct-to-consumer at itsmyleche.com and is FSA/HSA eligible. For more information, visit itsmyleche.com or follow them on Instagram, Facebook and TikTok. About Tiny Health Tiny Health is advancing lifelong health, from the first 1,000 days to the last, and addressing chronic disease through precision microbiome science. Founded in 2020 and built by microbiome scientists and physicians, its testing platform reveals whether your microbiome is trending toward resilience or imbalances using shotgun metagenomics, proprietary AI, and one of the world's largest longitudinal datasets. Trusted by families and health practitioners alike, its research-backed gut and vaginal tests are redefining the microbiome as a cornerstone of personalized health through every life stage. Learn more at tinyhealth.com and poweredbytiny.com. The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar. Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees. Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.